-
1
-
-
47949129948
-
Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant
-
Adams S, O'Neill DW, Nonaka D, Hardin E, Chiriboga L, Siu K, Cruz CM, Angiulli A, Angiulli F, Ritter E, Holman RM, Shapiro RL, Berman RS, Berner N, Shao Y, Manches O, Pan L, Venhaus RR, Hoffman EW, Jungbluth A, Gnjatic S, Old L, Pavlick AC, Bhardwaj N. 2008. Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J Immunol 181(1):776-784.
-
(2008)
J Immunol
, vol.181
, Issue.1
, pp. 776-784
-
-
Adams, S.1
O'neill, D.W.2
Nonaka, D.3
Hardin, E.4
Chiriboga, L.5
Siu, K.6
Cruz, C.M.7
Angiulli, A.8
Angiulli, F.9
Ritter, E.10
Holman, R.M.11
Shapiro, R.L.12
Berman, R.S.13
Berner, N.14
Shao, Y.15
Manches, O.16
Pan, L.17
Venhaus, R.R.18
Hoffman, E.W.19
Jungbluth, A.20
Gnjatic, S.21
Old, L.22
Pavlick, A.C.23
Bhardwaj, N.24
more..
-
2
-
-
77954959943
-
Immunotherapy for melanoma: Current status and perspectives
-
Alexandrescu DT, Ichim TE, Riordan NH, Marincola FM, Di Nardo A, Kabigting FD. Dasanu CA. 2010. Immunotherapy for melanoma: Current status and perspectives. J Immunother 33(6):570-590.
-
(2010)
J Immunother
, vol.33
, Issue.6
, pp. 570-590
-
-
Alexandrescu, D.T.1
Ichim, T.E.2
Riordan, N.H.3
Marincola, F.M.4
Di Nardo, A.5
Kabigting, F.D.6
Dasanu, C.A.7
-
3
-
-
0035417932
-
+ progenitor-derived dendritic cell vaccine
-
Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, Taquet S, Coquery S, Wittkowski KM, Bhardwaj N, Pineiro L, Steinman R, Fay J. 2001. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 61(17):6451-6458. (Pubitemid 32783251)
-
(2001)
Cancer Research
, vol.61
, Issue.17
, pp. 6451-6458
-
-
Banchereau, J.1
Palucka, A.K.2
Dhodapkar, M.3
Burkeholder, S.4
Taquet, N.5
Rolland, A.6
Taquet, S.7
Coquery, S.8
Wittkowski, K.M.9
Bhardwaj, N.10
Pineiro, L.11
Steinman, R.12
Fay, J.13
-
4
-
-
80051706186
-
TLR4 engagement during TLR3-induced pro-inflammatory signaling in dendritic cells promotes IL-10-mediated suppression of anti-tumor immunity
-
Bogunovic D, Manches O, Godefroy E, Yewdall A, Gallois A, Salazar AM, Marie I, Levy DE, Bhardwaj N. 2011. TLR4 engagement during TLR3-induced pro-inflammatory signaling in dendritic cells promotes IL-10-mediated suppression of anti-tumor immunity. Cancer Res. 71:5467-5476.
-
(2011)
Cancer Res
, vol.71
, pp. 5467-5476
-
-
Bogunovic, D.1
Manches, O.2
Godefroy, E.3
Yewdall, A.4
Gallois, A.5
Salazar, A.M.6
Marie, I.7
Levy, D.E.8
Bhardwaj, N.9
-
5
-
-
77954899030
-
Phase i study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates
-
Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, Gilson MM, Wang C, Selby M, Taube JM, Anders R, Chen L, Korman AJ, Pardoll DM, Lowy I, Topalian SL. 2010. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28(19):3167-3175.
-
(2010)
J Clin Oncol
, vol.28
, Issue.19
, pp. 3167-3175
-
-
Brahmer, J.R.1
Drake, C.G.2
Wollner, I.3
Powderly, J.D.4
Picus, J.5
Sharfman, W.H.6
Stankevich, E.7
Pons, A.8
Salay, T.M.9
McMiller, T.L.10
Gilson, M.M.11
Wang, C.12
Selby, M.13
Taube, J.M.14
Anders, R.15
Chen, L.16
Korman, A.J.17
Pardoll, D.M.18
Lowy, I.19
Topalian, S.L.20
more..
-
6
-
-
85044869427
-
Lymphodepletion and tumor burden govern clinical responses in patients with B-cell malignancies treated with autologous, CD19-targeted T cells
-
abstr 2534
-
Brentjens RJ, Riviere I, Park J, Davilla M, Wang X, Yeh R, Lamanna N, Frattini MG, Sadelain M. 2011. Lymphodepletion and tumor burden govern clinical responses in patients with B-cell malignancies treated with autologous, CD19-targeted T cells. J Clin Oncol 29:18s (abstr 2534).
-
(2011)
J Clin Oncol 29
-
-
Brentjens, R.J.1
Riviere, I.2
Park, J.3
Davilla, M.4
Wang, X.5
Yeh, R.6
Lamanna, N.7
Frattini, M.G.8
Sadelain, M.9
-
7
-
-
34748815649
-
GSK's antigen-specific cancer immunotherapy programme: Pilot results leading to Phase III clinical development
-
DOI 10.1016/j.vaccine.2007.06.038, PII S0264410X07007049
-
Brichard VG, Lejeune D. 2007. GSK's antigen-specific cancer immunotherapy programme: Pilot results leading to Phase III clinical development. Vaccine 25(Suppl 2):B61-B71. (Pubitemid 47488551)
-
(2007)
Vaccine
, vol.25
, Issue.SUPPL. 2
-
-
Brichard, V.G.1
Lejeune, D.2
-
8
-
-
77952472134
-
Chimeric antigen receptor-engineered T cells for immunotherapy of cancer
-
Cartellieri M, Bachmann M, Feldmann A, Bippes C, Stamova S, Wehner R, Temme A, Schmitz M. 2010. Chimeric antigen receptor-engineered T cells for immunotherapy of cancer. J Biomed Biotechnol 2010:956304.
-
(2010)
J Biomed Biotechnol
, vol.2010
, pp. 956304
-
-
Cartellieri, M.1
Bachmann, M.2
Feldmann, A.3
Bippes, C.4
Stamova, S.5
Wehner, R.6
Temme, A.7
Schmitz, M.8
-
9
-
-
75149127319
-
IL-7 is superior to IL-2 for ex vivo expansion of tumour-specific CD4(+) T cells
-
Caserta S, Alessi P, Basso V, Mondino A. 2010. IL-7 is superior to IL-2 for ex vivo expansion of tumour-specific CD4(+) T cells. Eur J Immunol 40(2):470-479.
-
(2010)
Eur J Immunol
, vol.40
, Issue.2
, pp. 470-479
-
-
Caserta, S.1
Alessi, P.2
Basso, V.3
Mondino, A.4
-
10
-
-
79959795786
-
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
-
Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA. 2011. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507-2516.
-
(2011)
N Engl J Med
, vol.364
, Issue.26
, pp. 2507-2516
-
-
Chapman, P.B.1
Hauschild, A.2
Robert, C.3
Haanen, J.B.4
Ascierto, P.5
Larkin, J.6
Dummer, R.7
Garbe, C.8
Testori, A.9
Maio, M.10
Hogg, D.11
Lorigan, P.12
Lebbe, C.13
Jouary, T.14
Schadendorf, D.15
Ribas, A.16
O'day, S.J.17
Sosman, J.A.18
Kirkwood, J.M.19
Eggermont, A.M.20
Dreno, B.21
Nolop, K.22
Li, J.23
Nelson, B.24
Hou, J.25
Lee, R.J.26
Flaherty, K.T.27
McArthur, G.A.28
more..
-
11
-
-
77958512341
-
IL-21 in the pathogenesis and treatment of skin diseases
-
Costanzo A, Chimenti MS, Botti E, Caruso R, Sarra M, Monteleone G. 2010. IL-21 in the pathogenesis and treatment of skin diseases. J Dermatol Sci 60(2):61-66.
-
(2010)
J Dermatol Sci
, vol.60
, Issue.2
, pp. 61-66
-
-
Costanzo, A.1
Chimenti, M.S.2
Botti, E.3
Caruso, R.4
Sarra, M.5
Monteleone, G.6
-
12
-
-
63149163677
-
The role of TNF superfamily members in T-cell function and diseases
-
Croft M. 2009. The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol 9(4):271-285.
-
(2009)
Nat Rev Immunol
, vol.9
, Issue.4
, pp. 271-285
-
-
Croft, M.1
-
13
-
-
77749279776
-
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
-
Curran MA, Montalvo W, Yagita H, Allison JP. 2010a. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA 107(9):4275-4280.
-
(2010)
Proc Natl Acad Sci USA
, vol.107
, Issue.9
, pp. 4275-4280
-
-
Curran, M.A.1
Montalvo, W.2
Yagita, H.3
Allison, J.P.4
-
15
-
-
65649147543
-
Braf(V600E) cooperates with Pten loss to induce metastatic melanoma
-
Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky WE, Jr., You MJ, DePinho RA, McMahon M, Bosenberg M 2009. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 41(5): 544-552.
-
(2009)
Nat Genet
, vol.41
, Issue.5
, pp. 544-552
-
-
Dankort, D.1
Curley, D.P.2
Cartlidge, R.A.3
Nelson, B.4
Karnezis, A.N.5
Damsky Jr., W.E.6
You, M.J.7
Depinho, R.A.8
McMahon, M.9
Bosenberg, M.10
-
16
-
-
63449095686
-
Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: A phase IIa trial
-
Davis ID, Brady B, Kefford RF, Millward M, Cebon J, Skrumsager BK, Mouritzen U, Hansen LT, Skak K, Lundsgaard D, Frederiksen KS, Kristjansen PE, McArthur G. 2009. Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: A phase IIa trial. Clin Cancer Res 15(6):2123-2129.
-
(2009)
Clin Cancer Res
, vol.15
, Issue.6
, pp. 2123-2129
-
-
Davis, I.D.1
Brady, B.2
Kefford, R.F.3
Millward, M.4
Cebon, J.5
Skrumsager, B.K.6
Mouritzen, U.7
Hansen, L.T.8
Skak, K.9
Lundsgaard, D.10
Frederiksen, K.S.11
Kristjansen, P.E.12
McArthur, G.13
-
17
-
-
18544380239
-
Tumor-associated B7- H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
-
Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Celis E, Chen L. 2002. Tumor-associated B7- H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med 8(8):793-800.
-
(2002)
Nat Med
, vol.8
, Issue.8
, pp. 793-800
-
-
Dong, H.1
Strome, S.E.2
Salomao, D.R.3
Tamura, H.4
Hirano, F.5
Flies, D.B.6
Roche, P.C.7
Lu, J.8
Zhu, G.9
Tamada, K.10
Lennon, V.A.11
Celis, E.12
Chen, L.13
-
18
-
-
54849437711
-
Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: Assessment of correlation between clinical response and vaccine parameters
-
Engell-Noerregaard L, Hansen TH, Andersen MH, Thor Straten P, Svane IM. 2009. Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: Assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother 58(1):1-14.
-
(2009)
Cancer Immunol Immunother
, vol.58
, Issue.1
, pp. 1-14
-
-
Engell-Noerregaard, L.1
Hansen, T.H.2
Andersen, M.H.3
Thor Straten, P.4
Svane, I.M.5
-
19
-
-
77956030786
-
Inhibition of mutated, activated BRAF in metastatic melanoma
-
Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB. 2010. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363(9):809-819.
-
(2010)
N Engl J Med
, vol.363
, Issue.9
, pp. 809-819
-
-
Flaherty, K.T.1
Puzanov, I.2
Kim, K.B.3
Ribas, A.4
McArthur, G.A.5
Sosman, J.A.6
O'dwyer, P.J.7
Lee, R.J.8
Grippo, J.F.9
Nolop, K.10
Chapman, P.B.11
-
20
-
-
48149096869
-
IL-21 induces in vivo immune activation of NK cells and CD8(+) T cells in patients with metastatic melanoma and renal cell carcinoma
-
Frederiksen KS, Lundsgaard D, Freeman JA, Hughes SD, Holm TL, Skrumsager BK, Petri A, Hansen LT, McArthur GA, Davis ID, Skak K. 2008. IL-21 induces in vivo immune activation of NK cells and CD8(+) T cells in patients with metastatic melanoma and renal cell carcinoma. Cancer Immunol Immunother 57(10):1439-1449.
-
(2008)
Cancer Immunol Immunother
, vol.57
, Issue.10
, pp. 1439-1449
-
-
Frederiksen, K.S.1
Lundsgaard, D.2
Freeman, J.A.3
Hughes, S.D.4
Holm, T.L.5
Skrumsager, B.K.6
Petri, A.7
Hansen, L.T.8
McArthur, G.A.9
Davis, I.D.10
Skak, K.11
-
21
-
-
0022478367
-
Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor
-
Grabstein KH, Urdal DL, Tushinski RJ, Mochizuki DY, Price VL, Cantrell MA, Gillis S, Conlon PJ. 1986. Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor. Science 232(4749): 506-508. (Pubitemid 16052365)
-
(1986)
Science
, vol.232
, Issue.4749
, pp. 506-508
-
-
Grabstein, K.H.1
Urdal, D.L.2
Tushinski, R.J.3
-
22
-
-
0035114558
-
Cancer statistics, 2001
-
Greenlee RT, Hill-Harmon MB, Murray T, Thun M. 2001. Cancer statistics, 2001. CA Cancer J Clin 51(1):15-36. (Pubitemid 32166444)
-
(2001)
Ca-A Cancer Journal for Clinicians
, vol.51
, Issue.1
, pp. 15-36
-
-
Greenlee, R.T.1
Hill-Harmon, M.B.2
Murray, T.3
Thun, M.4
-
23
-
-
77951134921
-
Interleukin-21: Updated review of Phase i and II clinical trials in metastatic renal cell carcinoma, metastatic melanoma and relapsed/refractory indolent non-Hodgkin's lymphoma
-
Hashmi MH, Van Veldhuizen PJ. 2010. Interleukin-21: Updated review of Phase I and II clinical trials in metastatic renal cell carcinoma, metastatic melanoma and relapsed/refractory indolent non-Hodgkin's lymphoma. Expert Opin Biol Ther 10(5):807-817.
-
(2010)
Expert Opin Biol Ther
, vol.10
, Issue.5
, pp. 807-817
-
-
Hashmi, M.H.1
Van Veldhuizen, P.J.2
-
24
-
-
84857596301
-
Improving umor Infiltrating lymphocyte survival, function for melanoma adoptive T-cell therapy through 4-1BB Costimulation
-
Hernandez JA, Li Y, Wang Y, Hwu P, Radvanyi L. 2009. Improving umor Infiltrating Lymphocyte Survival, Function for Melanoma Adoptive T-cell Therapy Through 4-1BB Costimulation. J Immunother International Society for Biological Therapy of Cancer 24th Annual Meeting Abstracts 32:944.
-
(2009)
J Immunother International Society for Biological Therapy of Cancer 24th Annual Meeting Abstracts
, vol.32
, pp. 944
-
-
Hernandez, J.A.1
Li, Y.2
Wang, Y.3
Hwu, P.4
Radvanyi, L.5
-
25
-
-
77954801079
-
Improved survival with ipilimumab in patients with metastatic melanoma
-
Hodi FS, O'Day SJ, McDermott DF, WeberRW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. 2010. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8): 711-723.
-
(2010)
N Engl J Med
, vol.363
, Issue.8
, pp. 711-723
-
-
Hodi, F.S.1
O'day, S.J.2
McDermott, D.F.3
Weberrw Sosman, J.A.4
Haanen, J.B.5
Gonzalez, R.6
Robert, C.7
Schadendorf, D.8
Hassel, J.C.9
Akerley, W.10
Van Den Eertwegh, A.J.11
Lutzky, J.12
Lorigan, P.13
Vaubel, J.M.14
Linette, G.P.15
Hogg, D.16
Ottensmeier, C.H.17
Lebbe, C.18
Peschel, C.19
Quirt, I.20
Clark, J.I.21
Wolchok, J.D.22
Weber, J.S.23
Tian, J.24
Yellin, M.J.25
Nichol, G.M.26
Hoos, A.27
Urba, W.J.28
more..
-
26
-
-
80052544390
-
A phase i trial of ipilimumab plus bevacizumab in patients with nresectable stage III or stage IV melanoma
-
(abstr 8511)
-
Hodi FS, Friedlander PA, Atkins MB, McDermott DF, Lawrence DP, Ibrahim N, Wu X, Zhou J, Giobbie-Hurder A, Murphy G, Hollman T, Velazquez E, Russell S, Dipiro P, Yap JT, Van Den Abbeele AD. 2011. A phase I trial of ipilimumab plus bevacizumab in patients with nresectable stage III or stage IV melanoma. J Clin Oncol 29:15S 2011 (abstr 8511).
-
(2011)
J Clin Oncol 29
, vol.15 S
, pp. 2011
-
-
Hodi, F.S.1
Friedlander, P.A.2
Atkins, M.B.3
McDermott, D.F.4
Lawrence, D.P.5
Ibrahim, N.6
Wu, X.7
Zhou, J.8
Giobbie-Hurder, A.9
Murphy, G.10
Hollman, T.11
Velazquez, E.12
Russell, S.13
Dipiro, P.14
Yap, J.T.15
Van Den Abbeele, A.D.16
-
27
-
-
45549099784
-
Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1
-
DOI 10.1056/NEJMoa0800251
-
Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R, Jungbluth A, Gnjatic S, Thompson JA, Yee C. 2008. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 358(25): 2698-2703. (Pubitemid 351860862)
-
(2008)
New England Journal of Medicine
, vol.358
, Issue.25
, pp. 2698-2703
-
-
Hunder, N.N.1
Wallen, H.2
Cao, J.3
Hendricks, D.W.4
Reilly, J.Z.5
Rodmyre, R.6
Jungbluth, A.7
Gnjatic, S.8
Thompson, J.A.9
Yee, C.10
-
28
-
-
56349142086
-
Immune modulation by melanoma-derived factors
-
Ilkovitch D, Lopez DM. 2008. Immune modulation by melanoma-derived factors. Exp Dermatol 17(12):977-985.
-
(2008)
Exp Dermatol
, vol.17
, Issue.12
, pp. 977-985
-
-
Ilkovitch, D.1
Lopez, D.M.2
-
29
-
-
77958503710
-
Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212
-
(abstr 2503)
-
Infante JR, Fecher LA, Nallapareddy S, Gordon MS, Flaherty KT, Cox DS, DeMarini DJ, Burris HA, Messersmith WA. 2010. Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212. JClin Oncol 28:15s (abstr 2503).
-
(2010)
JClin Oncol
, vol.28
-
-
Infante, J.R.1
Fecher, L.A.2
Nallapareddy, S.3
Gordon, M.S.4
Flaherty, K.T.5
Cox, D.S.6
Demarini, D.J.7
Burris, H.A.8
Messersmith, W.A.9
-
30
-
-
0037126021
-
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
-
Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. 2002. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 99(19):12293-12297.
-
(2002)
Proc Natl Acad Sci USA
, vol.99
, Issue.19
, pp. 12293-12297
-
-
Iwai, Y.1
Ishida, M.2
Tanaka, Y.3
Okazaki, T.4
Honjo, T.5
Minato, N.6
-
31
-
-
70350359819
-
Chemotherapy and biologic therapies for melanoma: Do they work?
-
Jilaveanu LB, Aziz SA, Kluger HM. 2009. Chemotherapy and biologic therapies for melanoma: Do they work? Clin Dermatol 27(6):614-625.
-
(2009)
Clin Dermatol
, vol.27
, Issue.6
, pp. 614-625
-
-
Jilaveanu, L.B.1
Aziz, S.A.2
Kluger, H.M.3
-
32
-
-
33750324618
-
Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes
-
Johnson LA, Heemskerk B, Powell DJ, Jr., Cohen CJ, Morgan RA, Dudley ME, Robbins PF, Rosenberg SA. 2006. Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. J Immunol 177(9):6548-6559. (Pubitemid 44628874)
-
(2006)
Journal of Immunology
, vol.177
, Issue.9
, pp. 6548-6559
-
-
Johnson, L.A.1
Heemskerk, B.2
Powell Jr., D.J.3
Cohen, C.J.4
Morgan, R.A.5
Dudley, M.E.6
Robbins, P.F.7
Rosenberg, S.A.8
-
33
-
-
70149114880
-
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen
-
Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, Kammula US, Royal RE, Sherry RM, Wunderlich JR, Lee CC, Restifo NP, Schwarz SL, Cogdill AP, Bishop RJ, Kim H, Brewer CC, Rudy SF, VanWaes C, Davis JL, Mathur A, Ripley RT, Nathan DA, Laurencot CM, Rosenberg SA. 2009. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114(3):535-546.
-
(2009)
Blood
, vol.114
, Issue.3
, pp. 535-546
-
-
Johnson, L.A.1
Morgan, R.A.2
Dudley, M.E.3
Cassard, L.4
Yang, J.C.5
Hughes, M.S.6
Kammula, U.S.7
Royal, R.E.8
Sherry, R.M.9
Wunderlich, J.R.10
Lee, C.C.11
Restifo, N.P.12
Schwarz, S.L.13
Cogdill, A.P.14
Bishop, R.J.15
Kim, H.16
Brewer, C.C.17
Rudy, S.F.18
Vanwaes, C.19
Davis, J.L.20
Mathur, A.21
Ripley, R.T.22
Nathan, D.A.23
Laurencot, C.M.24
Rosenberg, S.A.25
more..
-
34
-
-
77957350123
-
Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors
-
(abstr 8503)
-
Kefford R, Arkenau H, Brown MP, Millward M, Infante JR, Long GV, Ouellet D, Curtis M, Lebowitz PF, Falchook GS. 2010. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. J Clin Oncol 28:15s (abstr 8503).
-
(2010)
J Clin Oncol
, vol.28
-
-
Kefford, R.1
Arkenau, H.2
Brown, M.P.3
Millward, M.4
Infante, J.R.5
Long, G.V.6
Ouellet, D.7
Curtis, M.8
Lebowitz, P.F.9
Falchook, G.S.10
-
35
-
-
33750699642
-
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer
-
DOI 10.1158/1078-0432.CCR-06-1183
-
Kershaw MH, Westwood JA, Wang G, Eshhar Z, Mavroukakis SA, White DE, Wunderlich JR, Canevari S, Rogers-Freezer L, Chen CC, Yang JC, Rosenberg SA, Hwu P. 2006. A phase I study on adoptive immunotherapy using genemodified T cells for ovarian cancer. Clin Cancer Res 12(20 Pt 1):6106-6115. (Pubitemid 44703776)
-
(2006)
Clinical Cancer Research
, vol.12
, Issue.PART 1
, pp. 6106-6115
-
-
Kershaw, M.H.1
Westwood, J.A.2
Parker, L.L.3
Wang, G.4
Eshhar, Z.5
Mavroukakis, S.A.6
White, D.E.7
Wunderlich, J.R.8
Canevari, S.9
Rogers-Freezer, L.10
Chen, C.C.11
Yang, J.C.12
Rosenberg, S.A.13
Hwu, P.14
-
36
-
-
49149088707
-
Next generation of immunotherapy for melanoma
-
Kirkwood JM, Tarhini AA, Panelli MC, Moschos SJ, Zarour HM, Butterfield LH, Gogas HJ. 2008. Next generation of immunotherapy for melanoma. J Clin Oncol 26(20):3445-3455.
-
(2008)
J Clin Oncol
, vol.26
, Issue.20
, pp. 3445-3455
-
-
Kirkwood, J.M.1
Tarhini, A.A.2
Panelli, M.C.3
Moschos, S.J.4
Zarour, H.M.5
Butterfield, L.H.6
Gogas, H.J.7
-
37
-
-
33646794392
-
Checkpoint blockade in cancer immunotherapy
-
DOI 10.1016/S0065-2776(06)90008-X, PII S006527760690008X
-
Korman AJ, Peggs KS, Allison JP. 2006. Checkpoint blockade in cancer immunotherapy. Adv Immunol 90:297-339. (Pubitemid 43765802)
-
(2006)
Advances in Immunology
, vol.90
, pp. 297-339
-
-
Korman, A.J.1
Peggs, K.S.2
Allison, J.P.3
-
38
-
-
78449265422
-
Increased CD4 and CD8 memory T-cell proliferation after anti-OX40 administration to cancer patients: Immunologic assessment of a phase i clinical trial
-
Kovacsovics-Bankowski M, Walker E, Floyd K, Urba W, Curti B, Weinberg AD, Robert W. 2009. Increased CD4 and CD8 memory T-cell proliferation after anti-OX40 administration to cancer patients: Immunologic assessment of a phase I clinical trial. J Immunother International Society for Biological Therapy of Cancer 24th Annual Meeting Abstracts 32:952.
-
(2009)
J Immunother International Society for Biological Therapy of Cancer 24th Annual Meeting Abstracts
, vol.32
, pp. 952
-
-
Kovacsovics-Bankowski, M.1
Walker, E.2
Floyd, K.3
Urba, W.4
Curti, B.5
Weinberg, A.D.6
Robert, W.7
-
39
-
-
84857584456
-
PD-1 expression on MelanA-reactive T cells increases during progression to metastatic disease
-
[Epub ahead of print]
-
Kronig H, Falchner KJ, Odendahl M, Brackertz B, Conrad H, Muck D, Hein R, Blank C, Peschel C, Haller B, Schulz S, Bernhard H. 2011. PD-1 expression on MelanA-reactive T cells increases during progression to metastatic disease. Int J Cancer [Epub ahead of print].
-
(2011)
Int J Cancer
-
-
Kronig, H.1
Falchner, K.J.2
Odendahl, M.3
Brackertz, B.4
Conrad, H.5
Muck, D.6
Hein, R.7
Blank, C.8
Peschel, C.9
Haller, B.10
Schulz, S.11
Bernhard, H.12
-
40
-
-
78449242173
-
E4697 Phase III cooperative group study of yeast-derived granulocyte macrophage colony-stimulating factor (GM-CSF) versus placebo as adjuvant treatment of patients with completely resected stage III-IV melanoma
-
(abstr 8504)
-
Lawson DH, Lee SJ, Tarhini AA, Margolin KA, Ernstoff MS, Kirkwood JM. 2010. E4697 Phase III cooperative group study of yeast-derived granulocyte macrophage colony-stimulating factor (GM-CSF) versus placebo as adjuvant treatment of patients with completely resected stage III-IV melanoma. J Clin Oncol 28:15s (abstr 8504).
-
(2010)
J Clin Oncol
, vol.28
-
-
Lawson, D.H.1
Lee, S.J.2
Tarhini, A.A.3
Margolin, K.A.4
Ernstoff, M.S.5
Kirkwood, J.M.6
-
41
-
-
33646440024
-
Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: First clinical experience
-
Lamers CH, Sleijfer S, Vulto AG, Kruit WH, Kliffen M, Debets R, Gratama JW, Stoter G, Oosterwijk E. 2006. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: First clinical experience. J Clin Oncol 24(13):e20-e22.
-
(2006)
J Clin Oncol
, vol.24
, Issue.13
-
-
Lamers, C.H.1
Sleijfer, S.2
Vulto, A.G.3
Kruit, W.H.4
Kliffen, M.5
Debets, R.6
Gratama, J.W.7
Stoter, G.8
Oosterwijk, E.9
-
42
-
-
68549106145
-
Incubation of antigen-sensitized T lymphocytes activated with bryostatin 1+ionomycin in IL-7+IL-15 increases yield of cells capable of inducing regression of melanoma metastases compared to culture in IL-2
-
Le HK, Graham L, Miller CH, Kmieciak M, Manjili MH, Bear HD. 2009. Incubation of antigen-sensitized T lymphocytes activated with bryostatin 1+ionomycin in IL-7+IL-15 increases yield of cells capable of inducing regression of melanoma metastases compared to culture in IL-2. Cancer Immunol Immunother 58(10):1565-1576.
-
(2009)
Cancer Immunol Immunother
, vol.58
, Issue.10
, pp. 1565-1576
-
-
Le Graham, H.K.L.1
Miller, C.H.2
Kmieciak, M.3
Manjili, M.H.4
Bear, H.D.5
-
43
-
-
84857615389
-
IL-15 is superior to IL-2 in supporting Antigen-specific expansion and maintenance of T-cell memory in melanoma
-
Li Y, Hernandez J, Wu R, Hwu P, Radvanyi L. 2010. IL-15 is superior to IL-2 in supporting Antigen-specific expansion and maintenance of T-cell memory in melanoma. J Immunother International Society for Biological Therapy of Cancer 24th Annual Meeting Abstracts 33:988.
-
(2010)
J Immunother International Society for Biological Therapy of Cancer 24th Annual Meeting Abstracts
, vol.33
, pp. 988
-
-
Li, Y.1
Hernandez, J.2
Wu, R.3
Hwu, P.4
Radvanyi, L.5
-
44
-
-
79251496050
-
Phase II trial of high-dose interleukin-2 (IL-2) with priming and concomitant sargramostim (GM-CSF) in patients with advanced melanoma
-
(abstr 8560)
-
Lutzky J, Lawson DH, Enriquez-Nunez Y, Gabrilovich D. 2010. Phase II trial of high-dose interleukin-2 (IL-2) with priming and concomitant sargramostim (GM-CSF) in patients with advanced melanoma. J Clin Oncol 28:15s (abstr 8560).
-
(2010)
J Clin Oncol
, vol.28
-
-
Lutzky, J.1
Lawson, D.H.2
Enriquez-Nunez, Y.3
Gabrilovich, D.4
-
45
-
-
77950576363
-
Interferon alpha adjuvant therapy in patients with high-risk melanoma: A systematic review and metaanalysis
-
Mocellin S, Pasquali S, Rossi CR, Nitti D. 2010. Interferon alpha adjuvant therapy in patients with high-risk melanoma: A systematic review and metaanalysis. J Natl Cancer Inst 102(7):493-501.
-
(2010)
J Natl Cancer Inst
, vol.102
, Issue.7
, pp. 493-501
-
-
Mocellin, S.1
Pasquali, S.2
Rossi, C.R.3
Nitti, D.4
-
46
-
-
84857621448
-
Artifical microRNA targeting programmed death receptor-1 to enhance adoptive cell transfer therapy for cancer
-
Park TS, Inozume T, Ahmadzadeh M, Hanada K, Yang J, Rosenberg S, Morgan R. 2010. Artifical microRNA targeting programmed death receptor-1 to enhance adoptive cell transfer therapy for cancer. J Immunother Abstracts for the 25th Annual Scientific Meeting of the International Society for Biological Therapy of Cancer 33:863.
-
(2010)
J Immunother Abstracts for the 25th Annual Scientific Meeting of the International Society for Biological Therapy of Cancer
, vol.33
, pp. 863
-
-
Park, T.S.1
Inozume, T.2
Ahmadzadeh, M.3
Hanada, K.4
Yang, J.5
Rosenberg, S.6
Morgan, R.7
-
47
-
-
80054680991
-
Treating cancer with genetically engineered T cells
-
[Epub ahead of print]
-
Park TS, Rosenberg SA, Morgan RA. 2011. Treating cancer with genetically engineered T cells. Trends Biotechnol [Epub ahead of print].
-
(2011)
Trends Biotechnol
-
-
Park, T.S.1
Rosenberg, S.A.2
Morgan, R.A.3
-
48
-
-
78049474489
-
Interleukin-21 (IL-21) activity in patients (pts) with metastatic melanoma (MM)
-
(abstr 8507)
-
Petrella TM, Tozer R, Belanger K, Savage KJ, Wong R, Kamel-Reid S, Tron V. 2010. Interleukin-21 (IL-21) activity in patients (pts) with metastatic melanoma (MM). J Clin Oncol 28:15s (abstr 8507).
-
(2010)
J Clin Oncol
, vol.28
-
-
Petrella, T.M.1
Tozer, R.2
Belanger, K.3
Savage, K.J.4
Wong, R.5
Kamel-Reid, S.6
Tron, V.7
-
49
-
-
84859474960
-
Adoptive T cell therapy for metastatic melanoma: The MD Anderson experience
-
Radvanyi LG, Bernatchez C, Zhang M, Miller P, Glass M, Papadopoulos N, Hwu P. 2010. adoptive T cell therapy for metastatic melanoma: The MD Anderson experience. J Immunother Abstracts for the 25th Annual Scientific Meeting of the International Society for Biological Therapy of Cancer 33:863.
-
(2010)
J Immunother Abstracts for the 25th Annual Scientific Meeting of the International Society for Biological Therapy of Cancer
, vol.33
, pp. 863
-
-
Radvanyi, L.G.1
Bernatchez, C.2
Zhang, M.3
Miller, P.4
Glass, M.5
Papadopoulos, N.6
Hwu, P.7
-
50
-
-
77949407794
-
Multivariate evaluation of pharmacological responses in early clinical trials - A study of rIL-21 in the treatment of patients with metastatic melanoma
-
Rasmussen MA, Colding-Jorgensen M, Hansen LT, Bro R. 2010. Multivariate evaluation of pharmacological responses in early clinical trials - a study of rIL-21 in the treatment of patients with metastatic melanoma. Br J Clin Pharmacol 69(4):379-390.
-
(2010)
Br J Clin Pharmacol
, vol.69
, Issue.4
, pp. 379-390
-
-
Rasmussen, M.A.1
Colding-Jorgensen, M.2
Hansen, L.T.3
Bro, R.4
-
51
-
-
55949137090
-
Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma
-
(abstr. LBA9011)
-
Ribas A, Hauschild A, Kefford R, Punt CJ, Haanen JB, Marmol M, Garbe C, Gomez-Navarro J, Pavlov D, Marshall M. 2008. Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma. J Clin Oncol 26:15s (abstr. LBA9011).
-
(2008)
J Clin Oncol
, vol.26
-
-
Ribas, A.1
Hauschild, A.2
Kefford, R.3
Punt, C.J.4
Haanen, J.B.5
Marmol, M.6
Garbe, C.7
Gomez-Navarro, J.8
Pavlov, D.9
Marshall, M.10
-
52
-
-
68949208645
-
Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma
-
Ribas A, Kirkwood JM, Atkins MB, Whiteside TL, Gooding W, Kovar A, Gillies SD, Kashala O, Morse MA. 2009. Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma. J Transl Med 7:68.
-
(2009)
J Transl Med
, vol.7
, pp. 68
-
-
Ribas, A.1
Kirkwood, J.M.2
Atkins, M.B.3
Whiteside, T.L.4
Gooding, W.5
Kovar, A.6
Gillies, S.D.7
Kashala, O.8
Morse, M.A.9
-
53
-
-
79959772576
-
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
-
Robert C, Thomas L, Bondarenko I, O'Day S, M DJ, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH, Jr., Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD. 2011. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364(26):2517-2526.
-
(2011)
N Engl J Med
, vol.364
, Issue.26
, pp. 2517-2526
-
-
Robert, C.1
Thomas, L.2
Bondarenko, I.3
O'day, S.4
Dj, M.5
Garbe, C.6
Lebbe, C.7
Baurain, J.F.8
Testori, A.9
Grob, J.J.10
Davidson, N.11
Richards, J.12
Maio, M.13
Hauschild, A.14
Miller Jr., W.H.15
Gascon, P.16
Lotem, M.17
Harmankaya, K.18
Ibrahim, R.19
Francis, S.20
Chen, T.T.21
Humphrey, R.22
Hoos, A.23
Wolchok, J.D.24
more..
-
54
-
-
79952304769
-
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1
-
Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, Levy CL, Li YF, El-Gamil M, Schwarz SL, Laurencot C, Rosenberg SA. 2011. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 29(7):917-924.
-
(2011)
J Clin Oncol
, vol.29
, Issue.7
, pp. 917-924
-
-
Robbins, P.F.1
Morgan, R.A.2
Feldman, S.A.3
Yang, J.C.4
Sherry, R.M.5
Dudley, M.E.6
Wunderlich, J.R.7
Nahvi, A.V.8
Helman, L.J.9
MacKall, C.L.10
Kammula, U.S.11
Hughes, M.S.12
Restifo, N.P.13
Raffeld, M.14
Lee, C.C.15
Levy, C.L.16
Li, Y.F.17
El-Gamil, M.18
Schwarz, S.L.19
Laurencot, C.20
Rosenberg, S.A.21
more..
-
55
-
-
0024166189
-
Use of tumor-infiltrating lymphocyts and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report
-
Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, et al. 1988. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 319(25):1676-1680. (Pubitemid 19015247)
-
(1988)
New England Journal of Medicine
, vol.319
, Issue.25
, pp. 1676-1680
-
-
Rosenberg, S.A.1
Packard, B.S.2
Aebersold, P.M.3
Solomon, D.4
Topalian, S.L.5
Toy, S.T.6
Simon, P.7
Lotze, M.T.8
Yang, J.C.9
Seipp, C.A.10
Simpson, C.11
Carter, C.12
Bock, S.13
Schwartzentruber, D.14
Wei, J.P.15
White, D.E.16
-
56
-
-
27144500671
-
+ T cells in patients with melanoma
-
Rosenberg SA, Sherry RM, Morton KE, Scharfman WJ, Yang JC, Topalian SL, Royal RE, Kammula U, Restifo NP, Hughes MS, Schwartzentruber D, Berman DM, Schwarz SL, Ngo LT, Mavroukakis SA, White DE, Steinberg SM. 2005. Tumor progression can occur despite the induction of very high levels of self/ tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol 175(9):6169-6176. (Pubitemid 41508105)
-
(2005)
Journal of Immunology
, vol.175
, Issue.9
, pp. 6169-6176
-
-
Rosenberg, S.A.1
Sherry, R.M.2
Morton, K.E.3
Scharfman, W.J.4
Yang, J.C.5
Topalian, S.L.6
Royal, R.E.7
Kammula, U.8
Restifo, N.P.9
Hughes, M.S.10
Schwartzentruber, D.11
Berman, D.M.12
Schwarz, S.L.13
Ngo, L.T.14
Mavroukakis, S.A.15
White, D.E.16
Steinberg, S.M.17
-
57
-
-
65249173447
-
Adoptive cell therapy for the treatment of patients with metastatic melanoma
-
Rosenberg SA, Dudley ME. 2009. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 21(2):233-240.
-
(2009)
Curr Opin Immunol
, vol.21
, Issue.2
, pp. 233-240
-
-
Rosenberg, S.A.1
Dudley, M.E.2
-
58
-
-
79960299888
-
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy
-
Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, Morton KE, Laurencot CM, Steinberg SM, White DE, Dudley ME. 2011. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 17(13):4550-4557.
-
(2011)
Clin Cancer Res
, vol.17
, Issue.13
, pp. 4550-4557
-
-
Rosenberg, S.A.1
Yang, J.C.2
Sherry, R.M.3
Kammula, U.S.4
Hughes, M.S.5
Phan, G.Q.6
Citrin, D.E.7
Restifo, N.P.8
Robbins, P.F.9
Wunderlich, J.R.10
Morton, K.E.11
Laurencot, C.M.12
Steinberg, S.M.13
White, D.E.14
Dudley, M.E.15
-
59
-
-
66849095271
-
Serum vascular endothelial growth factor and fibronectin predict clinical response to highdose interleukin-2 therapy
-
Sabatino M, Kim-Schulze S, Panelli MC, Stroncek D, Wang E, Taback B, Kim DW, Deraffele G, Pos Z, Marincola FM, Kaufman HL. 2009. Serum vascular endothelial growth factor and fibronectin predict clinical response to highdose interleukin-2 therapy. J Clin Oncol 27(16):2645-2652.
-
(2009)
J Clin Oncol
, vol.27
, Issue.16
, pp. 2645-2652
-
-
Sabatino, M.1
Kim-Schulze, S.2
Panelli, M.C.3
Stroncek, D.4
Wang, E.5
Taback, B.6
Kim, D.W.7
Deraffele, G.8
Pos, Z.9
Marincola, F.M.10
Kaufman, H.L.11
-
60
-
-
77957744369
-
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
-
Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. 2010. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 207(10):2187-2194.
-
(2010)
J Exp Med
, vol.207
, Issue.10
, pp. 2187-2194
-
-
Sakuishi, K.1
Apetoh, L.2
Sullivan, J.M.3
Blazar, B.R.4
Kuchroo, V.K.5
Anderson, A.C.6
-
61
-
-
79957831345
-
Gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma
-
Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, Gailani F, Riley L, Conlon K, Pockaj B, Kendra KL, White RL, Kuzel TM, Curti B, Leming PD, Whitman ED, Balkissoon J, Reintgen DS, Kaufman H, Marincola FM, Merino MJ, Rosenberg SA, Choyke P, Vena D, Hwu P. 2011. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 364(22):2119-2127.
-
(2011)
N Engl J Med
, vol.364
, Issue.22
, pp. 2119-2127
-
-
Schwartzentruber, D.J.1
Lawson, D.H.2
Richards, J.M.3
Conry, R.M.4
Miller, D.M.5
Treisman, J.6
Gailani, F.7
Riley, L.8
Conlon, K.9
Pockaj, B.10
Kendra, K.L.11
White, R.L.12
Kuzel, T.M.13
Curti, B.14
Leming, P.D.15
Whitman, E.D.16
Balkissoon, J.17
Reintgen, D.S.18
Kaufman, H.19
Marincola, F.M.20
Merino, M.J.21
Rosenberg, S.A.22
Choyke, P.23
Vena, D.24
Hwu, P.25
more..
-
62
-
-
80051580618
-
Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths
-
Siegel R, Ward E, Brawley O, Jemal A. 2011. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61(4):212-236.
-
(2011)
CA Cancer J Clin
, vol.61
, Issue.4
, pp. 212-236
-
-
Siegel, R.1
Ward, E.2
Brawley, O.3
Jemal, A.4
-
63
-
-
5444251632
-
The impact of imiquimod, a toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand
-
Shackleton M, Davis ID, Hopkins W, Jackson H, Dimopoulos N, Tai T, Chen Q, Parente P, Jefford M, Masterman KA, Caron D, Chen W, Maraskovsky E, Cebon J. 2004. The impact of imiquimod, a toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Cancer Immun 4:9.
-
(2004)
Cancer Immun
, vol.4
, pp. 9
-
-
Shackleton, M.1
Davis, I.D.2
Hopkins, W.3
Jackson, H.4
Dimopoulos, N.5
Tai, T.6
Chen, Q.7
Parente, P.8
Jefford, M.9
Masterman, K.A.10
Caron, D.11
Chen, W.12
Maraskovsky, E.13
Cebon, J.14
-
64
-
-
84855739659
-
Adoptive transfer of short-term cultured tumor-infiltrating lymphocytes (young TIL) in metastatic melanoma patients
-
(abstr 8510)
-
Shapira-Frommer R, Besser M, Kuchuk I, Nave R, Zippel D, Treves A, Nagler A, Apter S, Shimoni A, Yerushalmi R, Ben-Ami E, Ben-Nun A, Markel G, Itzhaki O, Catane R, Schachter J. 2011. Adoptive transfer of short-term cultured tumor-infiltrating lymphocytes (young TIL) in metastatic melanoma patients. J Clin Oncol 29:18s (abstr 8510).
-
(2011)
J Clin Oncol
, vol.29
-
-
Shapira-Frommer, R.1
Besser, M.2
Kuchuk, I.3
Nave, R.4
Zippel, D.5
Treves, A.6
Nagler, A.7
Apter, S.8
Shimoni, A.9
Yerushalmi, R.10
Ben-Ami, E.11
Ben-Nun, A.12
Markel, G.13
Itzhaki, O.14
Catane, R.15
Schachter, J.16
-
65
-
-
78649649172
-
Melanoma immunotherapy
-
Sivendran S, Glodny B, Pan M, Merad M, Saenger Y. 2010. Melanoma immunotherapy. Mt Sinai J Med 77(6):620-642.
-
(2010)
Mt Sinai J Med
, vol.77
, Issue.6
, pp. 620-642
-
-
Sivendran, S.1
Glodny, B.2
Pan, M.3
Merad, M.4
Saenger, Y.5
-
66
-
-
79957917538
-
Ipilimumab
-
Sondak VK, Smalley KS, Kudchadkar R, Grippon S, Kirkpatrick P. 2011. Ipilimumab. Nat Rev Drug Discov 10(6):411-412.
-
(2011)
Nat Rev Drug Discov
, vol.10
, Issue.6
, pp. 411-412
-
-
Sondak, V.K.1
Smalley, K.S.2
Kudchadkar, R.3
Grippon, S.4
Kirkpatrick, P.5
-
67
-
-
0029037061
-
Expansion of immunostimulatory dendritic cells among the myeloid progeny of human CD34+ bone marrow precursors cultured with c-kit ligand, granulocyte-macrophage colonystimulating factor, and TNF-alpha
-
Szabolcs P, Moore MA, Young JW. 1995. Expansion of immunostimulatory dendritic cells among the myeloid progeny of human CD34+ bone marrow precursors cultured with c-kit ligand, granulocyte-macrophage colonystimulating factor, and TNF-alpha. J Immunol 154(11):5851-5861.
-
(1995)
J Immunol
, vol.154
, Issue.11
, pp. 5851-5861
-
-
Szabolcs, P.1
Moore, M.A.2
Young, J.W.3
-
68
-
-
55949113750
-
Phase i study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA)
-
(abstr 3007)
-
Sznol M, Hodi FS, Margolin K, McDermott DF, Ernstoff MS, Kirkwood JM, Wojtaszek C, Feltquate D, Logan T. 2008. Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA). J Clin Oncol 26:15s (abstr 3007).
-
(2008)
J Clin Oncol
, vol.26
-
-
Sznol, M.1
Hodi, F.S.2
Margolin, K.3
McDermott, D.F.4
Ernstoff, M.S.5
Kirkwood, J.M.6
Wojtaszek, C.7
Feltquate, D.8
Logan, T.9
-
69
-
-
77955917121
-
Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies
-
(abstr 2506)
-
Sznol M, Powderly JD, Smith DC, Brahmer JR, Drake CJ, McDermott DF, Lawrence DP, Wolchok JD, Topalian SL, Lowy I. 2010. Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies. J Clin Oncol 28:15s (abstr 2506).
-
(2010)
J Clin Oncol
, vol.28
-
-
Sznol, M.1
Powderly, J.D.2
Smith, D.C.3
Brahmer, J.R.4
Drake, C.J.5
McDermott, D.F.6
Lawrence, D.P.7
Wolchok, J.D.8
Topalian, S.L.9
Lowy, I.10
-
70
-
-
79952269861
-
Ipilimumab: A promising immunotherapy for melanoma
-
Thumar JR, Kluger HM. 2010. Ipilimumab: A promising immunotherapy for melanoma. Oncology (Williston Park) 24(14):1280-1288.
-
(2010)
Oncology (Williston Park)
, vol.24
, Issue.14
, pp. 1280-1288
-
-
Thumar, J.R.1
Kluger, H.M.2
-
71
-
-
77957319524
-
Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: Results from a phase I/II trial
-
Trepiakas R, Berntsen A, Hadrup SR, Bjorn J, Geertsen PF, Straten PT, Andersen MH, Pedersen AE, Soleimani A, Lorentzen T, Johansen JS, Svane JS. 2010. Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: Results from a phase I/II trial. Cytotherapy 12(6):721-734.
-
(2010)
Cytotherapy
, vol.12
, Issue.6
, pp. 721-734
-
-
Trepiakas, R.1
Berntsen, A.2
Hadrup, S.R.3
Bjorn, J.4
Geertsen, P.F.5
Straten, P.T.6
Andersen, M.H.7
Pedersen, A.E.8
Soleimani, A.9
Lorentzen, T.10
Johansen, J.S.11
Svane, J.S.12
-
72
-
-
0033517152
-
Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony- stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation
-
DOI 10.1084/jem.190.3.355
-
van Elsas A, Hurwitz AA, Allison JP. 1999. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GMCSF)- producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 190(3): 355-366. (Pubitemid 29374833)
-
(1999)
Journal of Experimental Medicine
, vol.190
, Issue.3
, pp. 355-366
-
-
Van Elsas, A.1
Hurwitz, A.A.2
Allison, J.P.3
-
73
-
-
33947506186
-
Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody
-
DOI 10.1200/JCO.2006.08.3311
-
Vonderheide RH, Flaherty KT, Khalil M, Stumacher MS, Bajor DL, Hutnick NA, Sullivan P, Mahany JJ, Gallagher M, Kramer A, Green SJ, O'Dwyer PJ, Running KL, Huhn RD, Antonia SJ. 2007. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 25(7):876-883. (Pubitemid 350002889)
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.7
, pp. 876-883
-
-
Vonderheide, R.H.1
Flaherty, K.T.2
Khalil, M.3
Stumacher, M.S.4
Bajor, D.L.5
Hutnick, N.A.6
Sullivan, P.7
Mahany, J.J.8
Gallagher, M.9
Kramer, A.10
Green, S.J.11
O'Dwyer, P.J.12
Running, K.L.13
Huhn, R.D.14
Antonia, S.J.15
-
74
-
-
33644805723
-
Low-dose outpatient chemobiotherapy with temozolomide, granulocyte- macrophage colony stimulating factor, interferon-α2b, and recombinant interleukin-2 for the treatment of metastatic melanoma
-
DOI 10.1200/JCO.2005.02.5791
-
Weber RW, O'Day S, Rose M, Deck R, Ames P, Good J, Meyer J, Allen R, Trautvetter S, Timmerman M, Cruickshank S, Cook M, Gonzalez R, Spitler LE. 2005. Low-dose outpatient chemobiotherapy with temozolomide, granulocyte- macrophage colony stimulating factor, interferon-alpha2b, and recombinant interleukin-2 for the treatment of metastatic melanoma. J Clin Oncol 23(35):8992-9000. (Pubitemid 46211483)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.35
, pp. 8992-9000
-
-
Weber, R.W.1
O'Day, S.2
Rose, M.3
Deck, R.4
Ames, P.5
Good, J.6
Meyer, J.7
Allen, R.8
Trautvetter, S.9
Timmerman, M.10
Cruickshank, S.11
Cook, M.12
Gonzalez, R.13
Spitler, L.E.14
-
75
-
-
78449243489
-
Immune checkpoint proteins: A new therapeutic paradigm for cancer-preclinical background: CTLA-4 and PD-1 blockade
-
Weber J. 2010. Immune checkpoint proteins: A new therapeutic paradigm for cancer-preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol 37(5):430-439.
-
(2010)
Semin Oncol
, vol.37
, Issue.5
, pp. 430-439
-
-
Weber, J.1
-
76
-
-
78650212294
-
GMCSF-interleukin fusion cytokines induce novel immune effectors that can serve as biopharmaceuticals for treatment of autoimmunity and cancer
-
Williams P, Galipeau J. 2011. GMCSF-interleukin fusion cytokines induce novel immune effectors that can serve as biopharmaceuticals for treatment of autoimmunity and cancer. J Intern Med 269(1):74-84.
-
(2011)
J Intern Med
, vol.269
, Issue.1
, pp. 74-84
-
-
Williams, P.1
Galipeau, J.2
-
77
-
-
77954242768
-
A fusion of GMCSF and IL-21 initiates hypersignaling through the IL-21Ralpha chain with immune activating and tumoricidal effects in vivo
-
Williams P, Rafei M, Bouchentouf M, Raven J, Yuan S, Cuerquis J, Forner KA, Birman E, Galipeau J. 2010. A fusion of GMCSF and IL-21 initiates hypersignaling through the IL-21Ralpha chain with immune activating and tumoricidal effects in vivo. Mol Ther 18(7):1293-1301.
-
(2010)
Mol Ther
, vol.18
, Issue.7
, pp. 1293-1301
-
-
Williams, P.1
Rafei, M.2
Bouchentouf, M.3
Raven, J.4
Yuan, S.5
Cuerquis, J.6
Forner, K.A.7
Birman, E.8
Galipeau, J.9
-
78
-
-
73149092567
-
Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria
-
Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS. 2009. Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin Cancer Res 15(23):7412-7420.
-
(2009)
Clin Cancer Res
, vol.15
, Issue.23
, pp. 7412-7420
-
-
Wolchok, J.D.1
Hoos, A.2
O'day, S.3
Weber, J.S.4
Hamid, O.5
Lebbe, C.6
Maio, M.7
Binder, M.8
Bohnsack, O.9
Nichol, G.10
Humphrey, R.11
Hodi, F.S.12
-
79
-
-
77949655286
-
Enhancing therapy of B16F10 melanoma efficacy through tumor vaccine expressing GPI-anchored IL-21 and secreting GM-CSF in mouse model
-
Zhao F, Dou J, He XF, Wang J, Chu L, Hu W, Yu F, Wu Y, Gu N. 2010. Enhancing therapy of B16F10 melanoma efficacy through tumor vaccine expressing GPI-anchored IL-21 and secreting GM-CSF in mouse model. Vaccine 28(16):2846-2852.
-
(2010)
Vaccine
, vol.28
, Issue.16
, pp. 2846-2852
-
-
Zhao, F.1
Dou, J.2
He, X.F.3
Wang, J.4
Chu, L.5
Hu, W.6
Yu, F.7
Wu, Y.8
Gu, N.9
|